Digested ddit4l product as diagnostic marker for alzheimer's disease
AssigneePlasmarker Biotechnology Co., Ltd
InventorsKai-cheng LI, Pu YOU
Life of this patent
Estimating the term…
Abstract
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Claims20
A method for diagnosing cognitive impairment or a neurodegenerative disease, and/or evaluating progression of said cognitive impairment or said neurodegenerative disease, comprising the step of:
- detecting, from a sample of a subject in need thereof, a content of a DNA damage-inducible transcript 4-like DDIT4L intron retention spliced product DIR, and/or of a nucleic acid encoding said DIR.
A diagnostic kit, comprising a substance for detecting a DNA damage-inducible transcript 4-like DDIT4L intron retention spliced product DIR, and/or a nucleic acid encoding said DIR, wherein said diagnostic kit is for use in diagnosis of cognitive impairment, and/or evaluation of progression of said cognitive impairment;
- and/or for use in diagnosis of a neurodegenerative disease, and/or evaluation of progression of said neurodegenerative disease.
A medicament screening method, comprising the step of:
- detecting changes in a content of DIR and/or of a nucleic acid encoding said DIR in a subject after administration of a candidate medicament, wherein said medicament is for use in prevention, treatment and/or alleviation of cognitive impairment and/or a neurodegenerative disease.
Dependencies are inferred from the claim text.